The inauguration ceremony for Etern's Wuxi headquarters is held in Wuxi New District on Oct 29. [Photo/WeChat account: xinwu_wx]
Shanghai-based Etern Therapeutics celebrated the inauguration of its Wuxi headquarters in Wuxi New District (WND) on Oct 29.
Etern is a leader in the field of targeted protein liquid-liquid phase segregation in China. In September 2023, the company established its Wuxi headquarters and a biological and chemical interdisciplinary research achievement transformation platform in WND, with an estimated investment of 2 billion yuan ($279 million).
Etern also planned to recruit scientific research talent from prestigious institutions to create a world-class liquid-liquid phase segregation research platform, aiming to incubate 10 to 15 preclinical projects and five to eight clinical projects.
The establishment of Etern's headquarters in WND is a testament to the district's dedication to developing its biomedical industry.
Home to 620 biomedical enterprises, WND's biomedical industry boasts a scale exceeding 100 billion yuan, accounting for 52.3 percent of Wuxi's total output in this sector.
